NOVN.SW vs. PFE
NOVN.SW (Novartis AG) and PFE (Pfizer Inc.) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, NOVN.SW returned 9.98%/yr vs -0.12%/yr for PFE. At a 0.34 correlation, their price movements are largely independent.
Performance
NOVN.SW vs. PFE - Performance Comparison
Loading charts...
Different Trading Currencies
NOVN.SW is traded in CHF, while PFE is traded in USD. To make them comparable, the PFE values have been converted to CHF using the latest available exchange rates.
Returns By Period
In the year-to-date period, NOVN.SW achieves a 8.91% return, which is significantly higher than PFE's 6.97% return. Over the past 10 years, NOVN.SW has outperformed PFE with an annualized return of 9.98%, while PFE has yielded a comparatively lower -0.12% annualized return.
NOVN.SW
- 1D
- 2.04%
- 1M
- 2.19%
- YTD
- 8.91%
- 6M
- 11.93%
- 1Y
- 22.96%
- 3Y*
- 14.41%
- 5Y*
- 12.76%
- 10Y*
- 9.98%
PFE
- 1D
- -1.31%
- 1M
- 2.62%
- YTD
- 6.97%
- 6M
- 1.62%
- 1Y
- 13.99%
- 3Y*
- -11.21%
- 5Y*
- -5.82%
- 10Y*
- -0.12%
NOVN.SW vs. PFE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NOVN.SW Novartis AG | 8.91% | 27.98% | 8.44% | 11.93% | 8.75% | -0.11% | -5.39% | 28.50% | 6.51% | 16.04% |
PFE Pfizer Inc. | 6.97% | -12.06% | 5.49% | -46.52% | -9.18% | 71.61% | -5.62% | -8.49% | 26.03% | 10.98% |
Correlation
The correlation between NOVN.SW and PFE is 0.36, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.36 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.28 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.31 |
Correlation (All Time) Calculated using the full available price history since Sep 3, 2007 | 0.34 |
The correlation between NOVN.SW and PFE shifts across timeframes, from 0.25 (3 years) to 0.36 (1 year), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NOVN.SW vs. PFE — Risk / Return Rank
NOVN.SW
PFE
NOVN.SW vs. PFE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novartis AG (NOVN.SW) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NOVN.SW | PFE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.74 | ||
| Sortino ratioReturn per unit of downside risk | +0.74 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.12 | +0.11 |
| Calmar ratioReturn relative to maximum drawdown | 2.29 | 1.20 | +1.09 |
| Martin ratioReturn relative to average drawdown | 5.53 | 2.44 | +3.10 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NOVN.SW | PFE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.34 | 0.60 | +0.74 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.72 | -0.23 | +0.94 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.55 | -0.00 | +0.55 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.48 | 0.10 | +0.38 |
Drawdowns
NOVN.SW vs. PFE - Drawdown Comparison
The maximum NOVN.SW drawdown since its inception was -42.25%, smaller than the maximum PFE drawdown of -63.23%. Use the drawdown chart below to compare losses from any high point for NOVN.SW and PFE.
Loading charts...
Drawdown Indicators
| NOVN.SW | PFE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -42.25% | -63.23% | +20.98% |
Max Drawdown (1Y)Largest decline over 1 year | -10.78% | -11.70% | +0.92% |
Max Drawdown (3Y)Largest decline over 3 years | -16.86% | -46.09% | +29.23% |
Max Drawdown (5Y)Largest decline over 5 years | -16.86% | -63.23% | +46.37% |
Max Drawdown (10Y)Largest decline over 10 years | -24.11% | -63.23% | +39.12% |
Current DrawdownCurrent decline from peak | -8.53% | -53.91% | +45.38% |
Average DrawdownAverage peak-to-trough decline | -11.40% | -21.49% | +10.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.43% | 5.75% | -1.32% |
Volatility
NOVN.SW vs. PFE - Volatility Comparison
Novartis AG (NOVN.SW) has a higher volatility of 6.01% compared to Pfizer Inc. (PFE) at 4.93%. This indicates that NOVN.SW's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NOVN.SW | PFE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.01% | 4.93% | +1.08% |
Volatility (6M)Calculated over the trailing 6-month period | 13.12% | 14.74% | -1.62% |
Volatility (1Y)Calculated over the trailing 1-year period | 18.53% | 23.61% | -5.08% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 17.81% | 25.98% | -8.17% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 18.23% | 24.78% | -6.55% |
Dividends
NOVN.SW vs. PFE - Dividend Comparison
NOVN.SW's dividend yield for the trailing twelve months is around 3.19%, less than PFE's 6.71% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NOVN.SW Novartis AG | 3.19% | 3.19% | 3.72% | 3.77% | 3.91% | 3.94% | 3.72% | 3.27% | 3.98% | 3.98% | 4.35% | 3.58% |
PFE Pfizer Inc. | 6.71% | 6.91% | 6.33% | 5.70% | 3.12% | 2.64% | 3.92% | 3.68% | 3.12% | 3.53% | 3.69% | 3.47% |
Financials
NOVN.SW vs. PFE - Financials Comparison
This section allows you to compare key financial metrics between Novartis AG and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
NOVN.SW and PFE have a correlation of 0.36, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for NOVN.SW and PFE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer